Full Text DA-97-002 NEUROBIOLOGICAL EFFECTS OF DRUG ABUSE THERAPIES NIH Guide, Volume 25, Number 22, July 5, 1996 RFA: DA-97-002 P.T. 34 Keywords: Drugs/Drug Abuse Treatment, Medical+ Nervous System National Institute on Drug Abuse Letter of Intent Receipt Date: September 18, 1996 Application Receipt Date: October 18, 1996 PURPOSE This Request for Applications (RFA) solicits research grant applications on the neurobiological effects of pharmacological and/or nonpharmacological drug abuse treatments upon structure and/or function of the human central nervous system. Results from such studies should ultimately provide a basis for the development and improvement of behavioral and medication treatment of patients with drug abuse disorders. This research program is intended to support individual research project grants and mentored career development awards on the clinical neurobiological effects of specific treatments for drug abuse disorders. Research using animals is not excluded, but any animal research in projects submitted under this RFA must serve an essential, but secondary role, in a predominantly clinical study. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000", a PHS-led national activity for setting priority areas. This RFA, Neurobiological Effects of Drug Abuse Therapies, is related to the priority area of alcohol and other drugs. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private such as colleges, universities, hospitals, laboratories, units of State and local government, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards or career development (K- series) awards. Awards to foreign institutions under other mechanisms are limited to three years. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) research project grants (R01), exploratory/developmental grant (R21), small grant (R03), and FIRST Award (R29), as well as Mentored Research Scientist Development (K01) and Mentored Clinical Scientist Development (K08) Awards. Most investigator-initiated research is supported by research project grants (R01). The total project period for an application submitted in response to this RFA may not exceed five years. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to customary peer review procedures. Applications judged to be non-responsive to the RFA will be held for the next regular receipt date. Because the nature and scope of the research proposed in response to this RFA may vary, the size of an award will vary also. The exploratory/developmental (R21) and small grant (R03) applications are limited to two years, non-renewable, and limited in direct cost amount per year (R03, $50,000; R21, $90,000) The R03 mechanism is intended for newer, less experienced investigators, investigators at institutions without a research tradition and experienced investigators wishing to change research directions or test new methods or techniques. The R21 mechanism is intended to encourage new research projects in underdeveloped research areas of drug abuse. Applicants for the R21 mechanism are expected to be experienced investigators whose previous research may have been distantly related areas to drug abuse (e.g., mental health) but whose expertise is applicable to drug abuse research. Mentored Research Scientist Development Award (K01) and Mentored Clinical Scientist Development Award (K08) are both mid-career grants intended to provide a period of sponsored research experience which will then enable the applicant to pursue an independent research career. The K01 and K08 awards support three to five years of mentored research experience and applicant are required to devote at least 75 percent time to the program. K01 Awards require a research or a health-professional doctorate or equivalent, while K08 Awards require a clinical degree or equivalent. There are additional special requirements for these mechanisms; if any applicant intends to apply for them under this RFA, they should contact the program official listed under the INQUIRIES section for further information. FUNDS AVAILABLE In FY 1997, it is anticipated that approximately ten to twelve awards may be funded at a total cost of up to $1.5 million. Approximately five regular grant (R01) awards at an average of $200,000, and five to seven awards under the other mechanisms are anticipated. RESEARCH OBJECTIVES Recent advances in clinical neurobiological methods have armed researchers with a powerful set of approaches to investigate how drugs of abuse affect the brain. However, little is known about how brain function may be influenced by drug abuse treatment. The principal goal of the research to be supported through this initiative is to identify how structure and/or function of neuronal systems are affected by specific treatments for drug abuse disorders. Toward this goal, NIDA is particularly interested in proposals that will utilize brain imaging or other state-of-the-art clinical neurobiological approaches for assessment of alterations in human brain function and structure during treatment for drug abuse disorders. The following specific research questions serve as a guide to the types of research areas that are encouraged in this RFA: o Important relationships between substance abuse disorders and comorbid neuropsychiatric disorders have been described, but the mechanisms underlying these interactions and their implications for drug abuse treatment remain poorly understood. Investigators are encouraged to determine the neurobiological mechanisms underlying these relationships in the drug-abuse treatment situation. o Concurrent use of multiple drugs of abuse poses a serious and frequent clinical challenge in drug abuse research and treatment. NIDA encourages studies aimed at detection and neurobiological characterization of differences in treatment response between single- and polydrug abusers. o Both pharmacological and behavioral treatment modalities have been shown to be effective, and clinically significant interactions between these modalities have been demonstrated. Very little is known, however, about the mechanisms underlying these interactions. Therefore, studies characterizing the mechanistic commonalities and differences between these treatment modalities are encouraged, as are studies that elucidate the neurobiological basis of interactions between combined treatments. o Similarly, studies that will detect and characterize neurobiological markers predictive of treatment efficacy are also of interest. o Recent research has demonstrated that gender differences may vary depending upon the combination of drugs of abuse. Further studies assessing gender differences in neurobiological response to treatment are strongly encouraged. Also, studies assessing ethnicity or HIV/AIDS status-differences in neurobiological effects of treatment are particularly welcome. All applications must address issues of project feasibility, implementation of the study, study design, sampling procedure, instrumentation and measurement, data collection, tracking of subjects, follow-up, and data analysis, as appropriate. Investigators are encouraged to offer HIV testing and counseling in accordance with current guidelines to subjects identified during the course of the research as being at risk for HIV acquisition or transmission. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by September 18, 1996, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application is being submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIDA staff to estimate the potential review workload and avoid conflict of interest in the review. The letter of intent is to be sent to: Director, Office of Extramural Program Review National Institute on Drug Abuse Parklawn Building, Room 10-42 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-2620 FAX: (301) 443-0538 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 5/95) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and from the Grants Information Office, Office of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, Room 3034, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, email: asknih@odrockm1.od.nih.gov. The FIRST (R29) award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The RFA label available in the PHS 398 (rev. 5/95) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, photocopies, in one package to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for courier/overnight mail service) At the time of submission, two additional copies of the application must be sent to: Director, Office of Extramural Program Review National Institute on Drug Abuse Parklawn Building, Room 10-42 5600 Fishers Lane Rockville, MD 20857 Applications must be received by October 18, 1996. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by DRG and for responsiveness by the NIDA staff. Incomplete and/or non- responsive applications will be returned to the applicant without further consideration. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NIDA in accordance with NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level by the National Advisory Council on Drug Abuse. Review Criteria o scientific technical merit and clinical significance and originality of proposed research; o relevance to the goals and objectives of this RFA; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human or animal subjects and the safety of the research environment. The above criteria apply to R01 applications and there are separate criteria for other mechanisms. When applying under other mechanisms, the applicants should obtain a copy of the relevant announcement from either their office of sponsored research (if located in a university) or from Grants Management Branch at NIDA (301-443-6710). These announcements contain instructions for the preparation of grant applications that must be strictly adhered to and describe review criteria that would be used by a peer review committee in evaluating submitted applications. In addition to the above mentioned criteria, relevance of the application to the goal and objectives of this RFA will also be an important consideration. AWARD CRITERIA Award criteria that will be used to make award decisions include: scientific merit as determined by peer review, availability of funds, and programmatic priorities. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Arthur MacNeill Horton, Jr., Ed.D. Division of Clinical and Services Research National Institute on Drug Abuse Parklawn Building, Room Number 10A-46 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-4877 FAX: (301) 443-2317 Email: ah61x@nih.gov Direct inquiries regarding fiscal matters to: Gary Fleming, J.D., M.A. Grants Management Branch National Institute on Drug Abuse Parklawn Building, Room Number 8A-54 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-6710 Email: gf6s@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |